Yoshiyuki Okumura

USPTO Granted Patents = 18 (Patent Applications = 3)

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 4)

Average Co-Inventor Count = 4.7

ph-index = 7

Forward Citations = 173(Granted Patents)

Location History:

Chita, JP (1997 - 2000)
Chita-gun, JP (2001 - 2009)
Aichi-ken, JP (2001 - 2011)
Aichi, JP (1996 - 2024)

Company Filing History:

Years Active: 1996-2024

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11964963 - Stable salt and crystal forms of 2-[3-({1-[2-(dimethylamino)ethyl]-2-(2,2-dimethylpropyl)-1H-1,3-benzodiazol-5-yl}sulfonyl)azetidin-1-yl]ethan-1-ol (2024-04-23),

2. 11555023 - Process for the differential solubility-driven asymmetric transformation of substituted 2H-chromene-3-carboxylic acids (2023-01-17),

3. 9447066 - Salts and crystal forms (2016-09-20),

4. 9447065 - Pharmaceutical composition (2016-09-20),

5. 8084476 - Substituted methyl aryl or heteroaryl amide compounds (2011-12-27),

6. 7534914 - Substituted methyl aryl or heteroaryl amide compounds (2009-05-19),

7. 7479564 - Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents (2009-01-20),

8. 7238714 - Aryl or heteroaryl amide compounds (2007-07-03),

9. 7141580 - Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents (2006-11-28),

10. 6713482 - Benzimidazole cyclooxygenase-2 inhibitors (2004-03-30),

11. 6710054 - Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents (2004-03-23),

12. 6444677 - 5-membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists (2002-09-03),

13. 6310079 - Benzimidazole cyclooxygenase-2 inhibitors (2001-10-30),

14. 6291520 - Hydroxamic acid and N-hydroxyurea derivatives and their use (2001-09-18),

15. 6063928 - 5-lipoxygenase inhibitors (2000-05-16),

Title: The Innovative Contributions of Yoshiyuki Okumura

Introduction

Yoshiyuki Okumura is a prominent inventor based in Aichi-ken, Japan. He has made significant contributions to the field of pharmaceuticals, holding a total of 18 patents. His work focuses on developing novel compounds and methods that enhance drug formulation and efficacy.

Latest Patents

One of Okumura's latest patents involves the creation of stable salt and crystal forms of a selective CB2 receptor agonist, known as Compound A. This invention provides a salt of Compound A, a crystal form, and a method for preparing the said salt, along with a pharmaceutical composition and its use. The salts of Compound A exhibit excellent pharmaceutical formulation properties, including high aqueous solubility and good chemical stability.

Another notable patent details a process for the differential solubility-driven asymmetric transformation of substituted 2H-chromene-3-carboxylic acids. This method allows for the preparation of a desired isomer by utilizing a chiral amine and ultraviolet light to enhance the solubility of the desired compound.

Career Highlights

Throughout his career, Yoshiyuki Okumura has worked with leading pharmaceutical companies, including Pfizer Corporation and Raqualia Pharma Inc. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Okumura has collaborated with notable colleagues in the field, including Kazunari Nakao and Takashi Mano. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in pharmaceutical research.

Conclusion

Yoshiyuki Okumura's innovative work in pharmaceuticals has led to significant advancements in drug formulation and development. His contributions continue to impact the industry positively, showcasing the importance of research and innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.